Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Vioxx Ruling May Curtail Health Plan Class Actions Against Drug Companies

  • News

Executive Summary

Third-party payers may find it more difficult to bring consumer fraud class actions against pharmaceutical companies following a state court ruling in Vioxx litigation

You may also be interested in...



Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation

Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation

Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation

Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation

Pharma Companies Swat Down Novel Theories Of Product Liability

For the last five years, brand name companies have been pulled into court to battle claims that they are liable for injuries caused by a generic version of their drug

Table

View full table

Tags:
Latest Headlines

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA

AAM Departures Lead To Change Of Chair For IGBA

Pharma Blames EU IVD Regulation For Clinical Trial Delays

See All
UsernamePublicRestriction

Register

PS048808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By